Abstract
Human IFN regulatory factor-5 (IRF-5) is a candidate tumor suppressor gene that mediates cell arrest, apoptosis, and immune activation. Here we show that ectopic IRF-5 sensitizes p53-proficient and p53-deficient colon cancer cells to DNA damage-induced apoptosis. The combination IFN-beta and irinotecan (CPT-11) cooperatively inhibits cell growth and IRF-5 synergizes with it to further promote apoptosis. The synergism is due to IRF-5 signaling since a striking defect in apoptosis and cell death was observed in IRF-5-deficient cells, which correlated well with a reduction in DNA damage-induced cellular events. Components of this IRF-5 signaling pathway are investigated including a mechanism for DNA damage-induced IRF-5 activation. Thus, IRF-5-regulated pathways may serve as a target for cancer therapeutics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / pathology*
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Apoptosis / drug effects
-
Apoptosis / genetics*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Camptothecin / pharmacology
-
Colonic Neoplasms / drug therapy
-
Colonic Neoplasms / genetics
-
Colonic Neoplasms / metabolism
-
Colonic Neoplasms / pathology*
-
DNA Damage*
-
DNA-Binding Proteins / biosynthesis
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / physiology*
-
Drug Synergism
-
HCT116 Cells
-
Humans
-
Interferon Regulatory Factors
-
Interferon-beta / administration & dosage
-
Interferon-beta / pharmacology
-
Irinotecan
-
Phosphorylation
-
Signal Transduction
-
Transcription Factors / biosynthesis
-
Transcription Factors / genetics
-
Transcription Factors / physiology*
-
Transfection
-
Tumor Suppressor Protein p53 / deficiency*
Substances
-
DNA-Binding Proteins
-
IRF5 protein, human
-
Interferon Regulatory Factors
-
Transcription Factors
-
Tumor Suppressor Protein p53
-
Irinotecan
-
Interferon-beta
-
Camptothecin